Ovarian cancer is the most lethal gynaecological malignancy and is the 4th most common cause of cancer-related death in women. High grade serous carcinoma (HGSC) is the most malignant form of ovarian cancer and accounts for up to 70% of all ovarian cancer.
My research project aims to investigate the inflammatory cytokine IL-6 as a major target in HGSC. We aim to investigate this by using blocking antibodies to IL-6 in combination with treatments that target other aspects of the peritoneal tumour microenvironment in mouse models of ovarian cancer.
These preclinical studies will help identify targeted therapies in the treatment of ovarian cancer.